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Schizophrenia may develop from disruptions in functional connectivity regulated by neurotransmitters such as 
dopamine and acetylcholine. The modulatory effects of these neurotransmitters might explain how 
antipsychotics attenuate symptoms of schizophrenia and account for the variable response to antipsychotics 
observed in clinical practice. Based on the putative mechanisms of antipsychotics and evidence of disrupted 
connectivity in schizophrenia, we hypothesised that functional network connectivity, as assessed using 
network-based statistics, would exhibit differences between treatment response subtypes of schizophrenia 
and healthy controls. Resting-state functional MRI data were obtained from 17 healthy controls as well as 
individuals with schizophrenia who responded well to first-line atypical antipsychotics (first-line responders; 
FLR, n=18), had failed at least two trials of antipsychotics but responded to clozapine (treatment-resistant 
schizophrenia; TRS, n=18), or failed at least two trials of antipsychotics and a trial of clozapine (ultra-
treatment-resistant schizophrenia; UTRS, n=16). Data were pre-processed using the Advanced Normalisation 
Toolkit and BrainWavelet Toolbox. Network connectivity was assessed using the Network-Based Statistics 
toolbox in Matlab. ANOVA revealed a significant difference in functional connectivity between groups that 
extended between cerebellar and parietal regions to the frontal cortex (p<0.05). Post-hoc T-tests revealed 
weaker network connectivity in individuals with UTRS compared with healthy controls but no other differences 
between groups. Results demonstrated distinct differences in functional connectivity between individuals with 
UTRS and healthy controls. Future work must determine whether these changes occur prior to the onset of 
treatment and if they can be used to predict resistance to antipsychotics during first-episode psychosis.  
Keywords: schizophrenia, treatment resistance, treatment response, magnetic resonance imaging, 
network based statistics, clozapine 
1. Introduction 
Post-mortem and in vivo studies have provided overwhelming evidence of aberrant functional 
connectivity in schizophrenia (Friston et al., 2016; Kanaan et al., 2005; Karbasforoushan and 
Woodward, 2012; Lynall et al., 2010; Menon, 2011; Zhou et al., 2007), supporting a role for 
dysconnection in the aetiology of the disorder (Stephan et al., 2009). Evidence suggests that 
functional dysconnectivity in schizophrenia could arise from the abnormal regulation of synaptic 
plasticity (Stephan et al., 2009). In particular, disrupted synaptic plasticity could be attributed to the 
downstream effects of dopamine, acetylcholine and serotonin on N-methyl-D-aspartate (NMDA) 
receptor-mediated synaptic function (Stephan et al., 2009). NMDA receptors mediate long-term 
potentiation (LTP) and long-term depression (LTD) via their effects on the functional state and 
number of α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionoic acid (AMPA) receptors at synaptic 
junctions (Lau and Zukin, 2007; Montgomery and Madison, 2004; Stephan et al., 2009). Therefore, 
modulating the activity or transport of NMDA receptors is likely to affect LTP and LTD by inducing 
downstream changes in brain connectivity (Stephan et al., 2009).  
Given the large body of literature identifying disrupted resting-state networks (RSNs) in 
schizophrenia (Lynall et al., 2010; Menon, 2011), the modulatory effects of these neurotransmitters 
on synaptic plasticity and overall functional connectivity might explain how antipsychotic drugs (D2 
and 5-HT2A receptor antagonists) attenuate symptoms of the disorder. However, while there is a 
general consensus that dysconnectivity is a hallmark of schizophrenia, several studies disagree about 
the nature of dysconnections within specific networks (Yu et al., 2012). Considering the 
heterogeneous nature of schizophrenia, it is conceivable that the discrepancies in functional 
dysconnectivity may be attributed to disrupted neurotransmission. If the functional network 
connectivity and pathophysiology of schizophrenia is different amongst individuals with the disorder, 
the likelihood of a single antipsychotic agent or class inducing remission in all individuals is 
improbable. In fact, what we observe is a division of schizophrenia into different response subtypes, 
with first- and second-generation antipsychotics providing relief for ~70% of individuals (Agid et al., 
2011) and clozapine (the gold-standard treatment for those who fail to respond to first-line therapy) 
providing relief for only 30%-70% of its recipients (Elkis, 2007; Essali et al., 2009; Kane and Correll, 
2016; Kane et al., 1988). Farooq and colleagues proposed subtyping schizophrenia according to 
treatment response, suggesting that division into subgroups, especially within the scope of research 
and drug development, could help us better understand and thereby treat this often disabling 
disorder (Farooq et al., 2013; Lee et al., 2015). This concept is supported by work demonstrating 
differences in dopaminergic and glutamatergic transmission between first-line responders (FLR) and 
individuals who fail to respond to treatment (Demjaha et al., 2014; Goldstein et al., 2015; Howes et 
al., 2015). 
Network-based statistics provide a useful tool for investigating the functional organisation of the 
human brain (Zalesky et al., 2010) and have been used to investigate differences between healthy 
controls and people with schizophrenia. Zalesky et al. reported a sub-network of 40 pairwise 
functional connections that were significantly weaker in those with schizophrenia when compared 
with healthy controls (Zalesky et al., 2010). This sub-network comprised fronto-temporal, occipito-
temporal, supplementary motor area-temporal and -occipital connections as well as connections 
within the cingulum (Zalesky et al., 2010), consistent with previously reported abnormalities (Ellison-
Wright et al., 2008; Fletcher et al., 1999; Fornito et al., 2009). A study by Cocchi et al. employing the 
same analytical technique identified three sub-networks with differing connectivity in people with 
schizophrenia and reported that although structure-function relationships were disrupted in one 
sub-network (lower correlation between functional connectivity and white matter integrity), the 
other  two sub-networks exhibited no such disruption (Cocchi et al., 2014). 
In contrast to more traditional methods for analysing resting-state brain data (such as independent 
components analysis (ICA)), network-based statistics consider the brain as a network, permitting 
investigation of the brain as an integrated system, rather than a collection of individual components 
(Bullmore and Sporns, 2009). By shifting away from low-dimensional ICA and seed-based correlation 
methods toward high-dimensional analysis, a richer examination of network connections is possible 
(Smith et al., 2013).  
Network organisation is likely to be influenced by disturbances in structural or functional 
connectivity and may vary between individuals exhibiting different types of disruption. Modulation 
of NMDA receptor-mediated synaptic plasticity by dopamine, serotonin and acetylcholine is 
hypothesised to account for the functional dysconnectivity observed in individuals with 
schizophrenia (Stephan et al., 2009). Should the underlying mechanisms responsible for modulation 
differ between treatment responders and non-responders, then network connectivity will also be 
affected to varying degrees. Given the growing body of literature indicating disrupted network 
connectivity in people with schizophrenia, it was hypothesised that network connectivity, as 
assessed using network-based statistics, would exhibit differences between treatment response 
subtypes of schizophrenia and healthy controls. We anticipated that those who failed to respond to 
first-line therapy and clozapine monotherapy would exhibit the greatest degree of dysconnectivity; 
however, disruptions in network organisation in treatment responders and those with treatment 
resistant schizophrenia (TRS; clozapine responders) were also expected. 
2. Methods 
2.1 Participants 
Details about participant recruitment have been described previously (Anderson et al., 2015). 
Briefly, individuals with a diagnosis of schizophrenia according to the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV) were recruited from mental health services in Auckland, New 
Zealand. Participants were enrolled into one of three study arms. Those who were responding well 
to first-line atypical antipsychotic monotherapy were assigned to the “first-line responder” (FLR) 
group; response to treatment was assessed by the treating psychiatrist, based on an improvement of 
positive symptoms and according to standard practice and current treatment guidelines for 
schizophrenia (Lehman et al., 2004; McGorry, 2005). Those who had failed at least two previous six-
to-eight-week trials of atypical antipsychotics and were now receiving clozapine were assigned to 
the “treatment-resistant” (TRS) group and participants who had failed at least two previous six-to-
eight-week trials of atypical antipsychotics and had also failed an adequate trial of clozapine 
monotherapy (at least 8 weeks post titration (Mouaffak et al., 2006)) were assigned to the “ultra-
treatment-resistant” (UTRS) group. The study was approved by the Northern X Regional Ethics 
Committee and all participants gave informed written consent. 
Duration of psychosis, Positive and Negative Syndrome Scale (PANSS) scores (Kay et al., 1987)  and 
past and present substance abuse (evaluated using the Alcohol, Smoking and Substance Involvement 
Screening Test (ASSIST; World Health Organisation) scale) were assessed at study entry. 
Antipsychotic dose at the time of assessment was converted to chlorpromazine equivalents using 
formulae with power transformation (Andreasen et al., 2010). In the absence of a power formula, 
amisulpride chlorpromazine equivalents were calculated using expert consensus regarding 
antipsychotic dosing (Gardner et al., 2010). Participants also provided a urine sample, which was 
screened for the presence of amphetamine, methamphetamine, benzodiazepines, cocaine, opiates 
and tetrahydrocannabinol (Medix Pro-Split Integrated Cup, Multi Drug Screening Test; Sobercheck 
Ltd). Participant demographics were compared across cohorts using the appropriate statistical tests 
in IBM SPSS Statistics Version 23.  
2.2. Data acquisition 
Structural and resting-state fMRI scans were acquired using a Siemens Magnetom Skyra 3T scanner. 
All but four of the participants were imaged using a 32-channel head coil. Two FLR and two with 
UTRS were imaged using a 20-channel head coil. T1-weighted images were acquired using a 
magnetization-prepared 180-degrees radio-frequency pulses and rapid gradient-echo (MPRAGE) 
sequence (Brant-Zawadzki et al., 1992). Acquisition parameters were as follows: repetition time (TR) 
1900 ms; echo time (TE) 2.39 ms; inversion time (TI) 900 ms; flip angle 9°; repetition 1; acceleration 
factor 2; field of view (FOV) 230 mm; matrix 256 x 256; voxel size 0.9 x 0.9 x 0.8 mm. 
Resting-state functional images were acquired over 8 minutes using echo-planar imaging (EPI) with 
the following parameters: TR 3000 ms, TE 30 ms; echo spacing 0.65 ms (0.62 ms for last 7 
participants, following software upgrade); phase-encode direction A>>P; 54 slices; 160 volumes; FOV 
192 mm; acceleration factor 2; matrix 64 x 64; voxel size 3.0 x 3.0 x 3.0 mm. Participants were asked 
to lie still with eyes open and concentrate on a fixation cross. Gradient distortion images for 
functional data were acquired using a gradient echo pulse sequence with the following parameters: 
TR 655 ms; TE1 4.92 ms; TE2 7.38 ms; voxel size 3.4 x 3.4 x 2.4 mm; phase-encode direction A>>P; 
FOV 220 mm. 
2.3. Image pre-processing 
Structural data were processed with the Advanced Normalization Toolkit (Tustison et al., 2014). 
Processing steps included initial N4 bias correction of raw structural images; brain extraction using a 
hybrid segmentation/template-based strategy;  construction of a study-specific template and 
segmentation priors based on all participants in the cohort; alternation between study-specific prior-
based segmentation and “pure tissue” posterior probability weighted bias correction using Atropos 
and N4; DiReCT-based cortical thickness estimation; normalization to a study-specific template and 
cortical parcellation using the AT116 anatomical parcellation template. 
Pre-processing of functional data was conducted using the BrainWavelet Toolbox 
(www.brainwavelet.org) (Patel et al., 2014).  Pre-processing steps have previously been reported 
(Simas et al., 2015) and included slice time correction; rigid-body head movement correction; affine 
co-registration to the skull-stripped structural image using a grey matter mask; registration to the 
MNI152_T1_1mm template in Talairach space (TT_N27); and spatial smoothing (6 mm full width at 
half maximum). Secondary motion artefacts in the fMRI data were modelled and removed using 
unsupervised timeseries despiking in the wavelet domain (Patel et al., 2014). Default parameters 
were used for despiking and were equivalent to those used by Patel et al. (Patel et al., 2014). 
Motion-related events across different frequencies were detected as chains of maximal and minimal 
wavelet coefficients. All coefficients belonging to a maximal or minimal chain were set to zero in the 
wavelet domain and the timeseries was recomposed. Due to the manner in which this algorithm 
detects these events, it is able to remove both slower, prolonged motion artefacts (such as spin 
history type effects) and higher frequency artefacts (such as spikes) (Patel et al., 2014). This method 
has been shown to out-perform standard despiking algorithms and achieve superior removal of 
motion artefacts in high-motion cohorts compared to scrubbing and regression-only models (Patel et 
al., 2014).  
Following wavelet despiking, further motion correction was performed using signal regression of the 
six motion parameters estimated during rigid-body head movement correction, their first order 
temporal derivatives and the cerebrospinal fluid (CSF) signal. High pass frequency filtering above 
0.02 Hz was then performed, followed by spatial smoothing (6 mm full width at half maximum 
Gaussian kernel) to minimise the influence of border placement during parcellation. 
Difference in head motion between groups was assessed using DVARS, the root mean square 
variance of frame-to-frame difference in percent signal change across all voxels of the brain (Smyser 
et al., 2010). Mean DVARS were compared between groups using a one-way ANOVA. 
Motion-corrected fMRI data were subjected to parcellation and divided into 116 parcels using the 
AFNI TT N27 EZ ML atlas. For each individual, the mean timeseries was extracted from each of the 
116 anatomically parcellated regions (nodes). The extracted signals were decomposed into four 
frequency bands by wavelet transform (Salvador et al., 2005): scale 1, 0.125–0.25 Hz; scale 2, 0.06–
0.125 Hz; scale 3, 0.03–0.06 Hz; scale 4, 0.02–0.03 Hz (Achard et al., 2006). Based on evidence from 
previous resting-state fMRI studies demonstrating that most salient differences between healthy 
controls and people with schizophrenia occur at frequencies in the range of 0.06 to 0.125 Hz (Achard 
et al., 2006; Lynall et al., 2010), the scale 2 wavelet was selected for comparisons in the current 
study. 
The strength of a connection between two nodes was the Pearson’s correlation coefficient of the 
wavelet coefficients. Positively and negatively weighted, undirected correlation matrices were 
derived and further analysis was undertaken using Matlab 2015a (MathWorks, U.S.A). All self-
connections were removed from correlation matrices prior to analysis. 
2.4. Network-based statistics 
Comparisons of functional network organisation were performed in Matlab 2015a using the Network 
Based Statistic (NBS) Toolbox (Zalesky et al., 2010). NBS seeks to identify arrangements of node-to-
node connections (structures) formed by links that surpass a given threshold (Zalesky et al., 2010). 
The topological extent of each structure is then used to determine its significance (Zalesky et al., 
2010). Permutation testing (using random assignment of each subject to a group) ascribes a p value 
(controlled for the family-wise error; FWE) to each structure based on its size (Zalesky et al., 2010). 
The total number of permutations for which the size of the permuted structure is greater than the 
size of the actual structure determines the p value for that arrangement of connections (Zalesky et 
al., 2010). Using NBS, a one-way ANOVA (FWE-corrected α≤0.05) applying equal weighting to all 
groups was performed to establish whether there was a difference between the groups. Data were 
permuted 5000 times using the network-based statistics method, applying a range of test statistic 
thresholds. The test statistic represents the relative weighting of an edge in a network. The size of 
the threshold affects the extent (and thereby visualisation) of the network but does not affect the 
statistical significance of connections within the network (Zalesky et al., 2010). This is illustrated in 
the visual depiction of network edges shown in Figure 1 (edges shown in light blue will be eliminated 
when viewed at a higher threshold but still contribute to the significant difference in connectivity 
between the groups). For optimal visualisation of sub-networks identified in the post-hoc analysis, a 
threshold of 4.9 was chosen, as it showed a substantial degree of dysconnection while still granting 
partition of dysconnections into meaningful subnetworks; lower thresholds produced networks that 
were too dense to enable inference and larger thresholds produced networks that were too sparse. 
Networks were determined based on their extent (i.e. the number of connections they comprised). 
Post-hoc T-tests (α≤0.05, corrected for multiple comparisons using the Bonferroni method) were 
performed to reveal the directionality of any differences established during the ANOVA (again, the 
network-based statistic method with 5000 permutations was employed). As only 1-tailed T-tests are 
permitted by the NBS software, all comparisons were run in both directions and corrected for using 
the Bonferroni method. Brain networks were visualized with the BrainNet Viewer 
(http://www.nitrc.org/projects/bnv/) (Xia et al., 2013). 
2.5. Influence of antipsychotic dose, symptom severity and drug-use on dysconnectivity 
As antipsychotic dose and symptom severity may have influenced dysconnectivity outcomes, 
associations between chlorpromazine equivalents/PANSS subscale scores and the strength of 
network connectivity in the ANOVA sub-network were assessed. Healthy controls were not 
interviewed using the PANSS but were given a contrived score of 30 for the purpose of this analysis. 
Likewise, all controls were given a chlorpromazine equivalent score of zero. The potential influence 
of recreational drug-use (measured using the ASSIST) was assessed only for those participants that 
completed the ASSIST questionnaire. 
To assess the effect of each covariate on the strength of connectivity in the ANOVA sub-network, 
first, the binary sub-network matrix (with ones representing edges included in the sub-network) was 
linearised and multiplied by the edge strength information contained in each participant’s scale 2 
wavelet correlation matrix; this produced a matrix containing connection strength information for all 
edges contained in the sub-network for every participant. As correlation matrices were positively 
and negatively weighted, the absolute value of connection strength was used for further analysis (to 
retain weight information without positive and negative values cancelling one another out). The 
mean absolute connection strength across all edges of the sub-network was then compared 
between groups, adding chlorpromazine equivalents, PANSS sub-scale scores and ASSIST scores as 
covariates. Limited degrees of freedom required that each covariate be assessed in a separate 
analysis of covariance (ANCOVA). Pairwise comparisons of main effects were conducted, using the 
Bonferroni correction for multiple comparisons. 
2.6. Validation of results using alternative parcellation scheme 
To ensure that the results obtained with the AFNI 116 parcellation scheme were robust, findings 
were validated using an alternative parcellation scheme. To ensure full coverage of the cerebrum 
and cerebellum, brain data was parcellated using a custom-made 1 mm MNI atlas combining parcels 
from the Human Brainnetome Atlas (Fan et al., 2016) (modified from the original Desikan–Killiany 
(DK) atlas (Desikan et al., 2006)) and the probabilistic MR atlas of the human cerebellum (MNIflirt-
maxprob-thr50-1mm) (Diedrichsen et al., 2009). The final atlas contained 272 parcels; any 
overlapping voxels were removed from the atlas to prevent bias toward one parcellation scheme or 
the other. As before, motion-corrected fMRI data from participants were subjected to parcellation 
and the mean timeseries was extracted from each of the 272 regions. Scale 2 wavelet data were 
used for further analysis in NBS.  
 
3. Results 
3.1. Participant demographics 
Data from 17 healthy controls, 18 FLR, 18 individuals with TRS and 16 individuals with UTRS were 
included in the analysis. Demographic data are presented in Table 1.  
3.2. Between-groups comparison of head motion 
Mean (standard deviation) DVARS were 11.1 (1.6), 12.7 (2.8), 12.6 (3.2) and 13.1 (4.3) for controls, 
FLR, those with TRS and those with UTRS, respectively; ANOVA revealed no significant differences in 
head motion between groups (F=1.205; p=0.315). 
3.3. Network-based statistics  
Network organisation across groups was compared using network-based statistics (Zalesky et al., 
2010). ANOVA revealed a significant difference in connectivity between groups that extended 
primarily between cerebellar and parietal regions to the frontal cortex (p<0.05; Figure 1). Post-hoc T-
tests revealed significantly weaker network connectivity in individuals with UTRS compared to 
healthy controls (p<0.05, Bonferroni corrected) but no differences in connectivity between controls 
and FLR or those with TRS or between any of the schizophrenia cohorts. Differences observed in the 
post-hoc T-tests mirrored those identified in the ANOVA.  
Dysconnections in those with UTRS divided into three sub-networks, representing cerebellar-frontal 
dysconnections (Figure 2, sub-network 1; p<0.012 corrected), cingulo-frontal-temporal 
dysconnections (Figure 2, sub-network 2; p=0.036 corrected) and fronto-parietal dysconnections 
(Figure 2, sub-network 3; p=0.036 corrected). Mean absolute connection strengths for each sub-
network were compared between groups and are illustrated in Figure S1 of the supplementary 
material. In all cases, healthy controls had the greatest mean connection strength and those with 
UTRS the weakest connection strength. FLR generally had weaker mean connection strength than 
those with TRS; however, as mentioned above, no significant differences were observed between 
these groups. 
3.4. Influence of antipsychotic dose and symptom scores on dysconnectivity 
Details of the effects of chlorpromazine equivalents, PANSS sub-scores and ASSIST score on the 
relationship between treatment group and sub-network connection strength are provided in 
supplementary table S1. Briefly, no effect of any baseline characteristic was observed in the ANCOVA 
(p>0.05 for all covariates). Post-hoc pairwise comparisons revealed some additional effects of 
treatment group (see supplementary table S1); however these effects should be interpreted with 
care, given that healthy controls were assigned contrived values for chlorpromazine equivalents and 
PANSS scores and not all participants completed the ASSIST questionnaire.  
3.5. Validation of results using alternative parcellation scheme 
To validate findings obtained with the AFNI 116 parcellation scheme, data were analysed using an 
alternative 272-parcellation method. Network-based statistics revealed a statistically significant 
effect between groups (ANOVA: p<0.05), attributable to a significant reduction in connectivity in 
those with UTRS compared with healthy controls (post-hoc T-test: p<0.05, Bonferroni corrected). 
Two sub-networks were identified, which most closely resembled sub-networks 1 and 3 from the 
original analysis (details provided in supplementary Figure S2). 
 
4. Discussion 
Here, we investigated whether disruptions in resting-state functional connectivity are associated 
with resistance to antipsychotic treatment in people with schizophrenia. Network-based statistics 
revealed large disruptions in functional connectivity across three sub-networks in those with UTRS 
compared to healthy controls, but no significant differences between any other groups. A key 
distinction between this study and previous network-based statistics studies in schizophrenia was 
the identification of a large sub-network (sub-network 1) consisting primarily of interhemispheric 
dysconnections between cerebellar and prefrontal nodes. Prior exclusion of cerebellar nodes had 
prevented identification of any potential cerebellar dysconnections in previous work, though other 
nodes identified as dysconnected in the current study are in agreement with previous findings 
(Cocchi et al., 2014; Zalesky et al., 2010). 
The identification of a dysconnected cerebellar network in UTRS follows results from voxel-based 
morphometry analysis in the same cohort of individuals that identified, among other disruptions, a 
reduction in grey matter density in the left cerebellum of individuals with UTRS in contrast to healthy 
controls (Anderson et al., 2015). Likewise, regions of sub-network 2, including middle temporal gyri, 
anterior cingulate gyrus and ventromedial prefrontal cortices, exhibited decreased grey matter 
density in people with UTRS compared with healthy controls (Anderson et al., 2015). Post-mortem 
studies indicate that grey matter reductions observed in schizophrenia are attributable to a decrease 
in the cortical neuropil, comprised of axons, dendrites and pre- and post-synaptic terminals of 
cortical neurons (Glantz et al., 2006). Functional dysconnections in sub-networks 1 and 2 of those 
with UTRS may therefore arise from disruptions to synaptic communication at the cellular level. 
Unlike nodes within the first two sub-networks, regions of sub-network 3 (consisting of prefrontal 
and medial parietal cortices) were not associated with areas of grey matter loss in those with UTRS 
(Anderson et al., 2015). Cocchi et al. previously showed that functional dysconnections identified 
using network-based statistics correlate with decreases in structural integrity in only some cases; 
functional and structural dysconnections may not always occur concurrently (Cocchi et al., 2014). 
Consequently, the underlying pathophysiology of sub-network 3 may differ from that of sub-
networks 1 and 2.  
This is the first study to employ network-based statistics to identify functional biomarkers of 
treatment resistance in people with schizophrenia. Although individuals with this disorder have been 
experiencing variable responses to antipsychotic medication for decades (Kane and Correll, 2016), 
until recently, few studies had sought to investigate structural, functional or neurochemical 
differences between FLR, those with TRS and those with UTRS (Gillespie et al., 2017). With regard to 
functional differences, Molina Rodriguez et al. identified lower perfusion in the thalamus, left basal 
ganglia and right prefrontal regions in those who developed UTRS (Rodriguez et al., 1996) and found 
that individuals with high metabolic activity in the dorsolateral prefrontal cortex were more likely to 
experience improvements in negative symptoms following administration of clozapine (Molina et al., 
2003). Although no statistically significant differences in functional connectivity were observed 
between those with TRS and UTRS in the current study, connection strength across all three sub-
networks was lower in those with UTRS compared with TRS and a lack of significance in this case 
may stem from insufficient statistical power.  
More recent research has mainly focused on white matter disruptions in treatment-resistant or 
clozapine-eligible individuals rather than those with UTRS but may still provide context in which to 
consider the current findings. Of specific interest to the current study, Reis Marques et al. conducted 
an investigation in first-episode psychosis to determine whether pre-treatment fractional anisotropy 
(FA) could distinguish responders from non-responders to a 12 week course of antipsychotics (Reis 
Marques et al., 2014). They identified lower FA in non-responders compared with responders in 
several white matter tracts, including the uncinate, stria terminali, superior frontal-occipital tract, 
CC, internal and external capsule and corona radiata (Reis Marques et al., 2014). Unpublished work 
from our lab has revealed lower FA in people with TRS compared with healthy controls (and those 
with UTRS) but no significant differences between healthy controls and FLR or people with UTRS. 
These findings in combination with those of the current study suggest that the disruptions in 
functional connectivity observed in those with UTRS are unlikely to be due to abnormalities in white 
matter structure, despite reports of white matter disruption in those eligible for and responding to 
clozapine.  
This study benefits from a well characterised cohort of participants, demonstrating similar degrees 
of symptom severity and duration of illness, as well as similar ratios of male to female participants. 
Statistical comparison of participants who completed the ASSIST questionnaire revealed higher rates 
of drug-taking behaviour in FLR and those with UTRS compared with healthy controls. However, no 
statistically significant differences in positive drug screen on the day of testing and no effect of 
ASSIST score on connection strength were observed, suggesting that exposure to recreational drugs 
was unlikely to account for the differences observed between groups in the current study. Similarly, 
although prescribed antipsychotic dose (measured in chlorpromazine equivalents) was higher in 
those with UTRS compared with FLR and those with TRS, no effect of chlorpromazine equivalents on 
network connection strength was observed. The same was true for symptom severity. 
A common criticism of fMRI (and particularly connectomics) studies is a lack of reproducibility, both 
within and between study cohorts (Thirion et al., 2014). To evaluate the robustness of the current 
findings, data were subjected to two parcellation schemes (116 AFNI parcellation and 272 custom-
made parcellation). Results of the second parcellation corroborated those of the first, demonstrating 
statistically significant dysconnections in the UTRS group compared with healthy controls. Sub-
networks were also similar across parcellation schemes. Although the 272 parcellation gave only two 
sub-networks where the 116 parcellation gave three, regions of the missing sub-network were 
incorporated into the two that remained.  
The study’s cross–sectional design imparts a degree of uncertainty about the underlying cause of 
observed differences. Future work is required to establish whether differences between controls and 
individuals with UTRS exist at treatment onset. If so, functional connectivity may become a useful 
predictive biomarker of treatment resistance in schizophrenia. 
Results of the current analysis extend on those of earlier studies utilising network-based statistics to 
reveal functional dysconnectivity in people with schizophrenia (Cocchi et al., 2014; Zalesky et al., 
2010). Here we have demonstrated that ultra-treatment-resistance is associated with large 
disruptions to network connectivity, in particular cerebellar-frontal networks, in people with 
schizophrenia. Although we did not observe any significant differences between FLR, those with TRS 
and those with UTRS in the current study, investigation of a larger cohort of participants studied 
longitudinally may reveal some relationship between degree of dysconnection and treatment 
resistance.  
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